Information Provided By: 
Fly News Breaks for May 22, 2019
VEEV
May 22, 2019 | 07:08 EDT
Stifel analyst Tom Roderick raised his price target on Veeva shares to $150 from $130 ahead of the company's Q1 report due next Wednesday, telling investors that his checks suggest that Veeva has made substantial progress in both its product and go-to-market efforts with its Clinical Data Management and Clinical Operations suites. The analyst, who believes Veeva is well positioned to capture additional Clinical wallet share, keeps a Buy rating on the stock.
News For VEEV From the Last 2 Days
There are no results for your query VEEV
